|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Schizophrenia | |||||
| 2 | More general conditions related to this trial | ||||
| Mental Disorders | |||||
| Schizophrenia and Disorders with Psychotic Features | |||||
| 3 | Interventions listed in this trial | ||||
| SM-13496 | |||||
| 4 | Sponsors listed in this trial | ||||
| Sumitomo Pharmaceuticals America | |||||